Atrial fibrillation (AF) accounts for 2% of the total presentations to the emergency department
(ED) and represents the most frequent arrhythmic cause for hospitalization. It steadily …

Real-world data are a well-recognized component within the drug lifecycle, and such data
are generated from a range of sources and study designs, including claims databases …

Background Stroke prevention with oral anticoagulant (OAC) therapy, including non-vitamin
K antagonist oral anticoagulants (NOACs), is recommended in patients with atrial fibrillation …

Background: New oral anticoagulant agents (NOACs) are valid alternatives for vitamin K
antagonists (VKA) in patients with non-valvular atrial fibrillation (NVAF) for stroke prevention …

A large number of patients who sustain a traumatic intracranial haemorrhage (tICH) are
taking anti-thrombotic (AT) medications at the time of injury. These are stopped acutely, but …

Background The purpose of the study was to examine the association between the type of
preceding oral anticoagulant use (warfarin or direct oral anticoagulants [DOACs]) and in …

Background Real-world evidence on factor Xa inhibitor (rivaroxaban) prescribing patterns,
safety, and efficacy in patients with non-valvular atrial fibrillation (NVAF) and venous …

Abstract Background and purpose Intravenous Thrombolysis (IVT) prior to Mechanical
Thrombectomy (MT) for Acute Ischaemic Stroke (AIS) due to Large-Vessel Occlusion (LVO) …

East Asians are reportedly at high risk of anticoagulant-related bleeding; therefore, some
physicians prefer to prescribe low-dose direct oral anticoagulants (DOACs). Little is known …

Abstract Background Direct oral anticoagulants (DOACs) have been proven to be effective
and safe for prevention of ischemic stroke and systemic embolism in patients with non …